# Form 8-K

# Current Report

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):    **August 28,  2015**

# Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)

| **Delaware** | **000-50679** | **77-0487658** |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

**149 Commonwealth Drive**
**Menlo Park, CA  94025**
(Address of principal executive offices, with zip code)

**(650) 327-3270**
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On August 28, 2015, Steven Lo, Senior Vice President, Oncology of Corcept Therapeutics Incorporated ("Corcept"), provided notice of his decision to resign from Corcept effective September 4, 2015 in order to accept a position with another company.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS INCORPORATED**

Date:  September 3, 2015

By:    /s/  G. Charles Robb
       G. Charles Robb
       Chief Financial
Officer

-3-